On September 16, 2008, the U.S. Food and Drug Administration (
Site Search
Showing 81 - 90 of 119 results
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
New Agreement Increases Potential Payments to EPIX by up to $37.7 Million
Press Release
|
|
6 min read
News
|
|
1 min read
The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.
News
|
|
3 min read